The mechanism: Biogen's entire Alzheimer's franchise rests on a single piece of paper: National Coverage Determination 200.3, the CMS rule that lets Medicare pay for anti-amyloid antibodies like Leqembi. That NCD isn't statute — it's an administrative determination CMS itself wrote in 2022 and loosened in 2023, and what CMS writes, CMS can revisit. With HHS under new leadership newly hostile to expensive interventions with thin outcome data and openly gutting other big-ticket coverage pathways (it's already moved to unwind favorable reimbursement treatment for breakthrough-designated devices), a re-opened NCD proceeding on amyloid antibodies — tightening the mild-cognitive-impairment eligibility window, reinstating tougher registry/CED evidence bars, or trimming diagnostic-imaging coverage — is a live tail risk that Wall Street is pricing as background noise. It isn't. Medicare is essentially the entire addressable market for a drug given to elderly MCI/mild-AD patients; a narrower NCD doesn't dent Leqembi's growth curve, it deletes it.
Biogen's Exposure Problem: The One CMS Memo Standing Between Leqembi and a Re-Rating
Leqembi's entire commercial future hinges on one administrative determination CMS wrote in 2022 — and a cost-skeptical HHS could reopen it at any time.
| Ticker | Company | 1-year change |
|---|---|---|
| VRTX | Vertex Pharmaceuticals | +22.1% |
Medicare is essentially the entire addressable market for Leqembi — a narrower coverage rule doesn't dent the growth curve, it deletes it.
Who cashes in: If CMS moves to re-tighten amyloid-drug coverage, capital simply rotates to Alzheimer's approaches that don't depend on the same fragile coverage clause. Amgen AMGN is running late-stage anti-tau and combination Alzheimer's programs that would inherit share of voice (and eventually share of spend) if amyloid-only NCD risk becomes a market theme — its diversified base means an AD setback for Biogen isn't existential for anyone rotating capital its way. Vertex VRTX and Intellia NTLA aren't Alzheimer's plays today, but both are the natural landing spots for generalist biotech money exiting a name whose thesis has become "one CMS memo away from re-rating" — capital doesn't sit in cash, it rotates to names with mechanism diversity and gene-editing/curative optionality that isn't hostage to a single reimbursement determination.
Who is exposed: Biogen BIIB is the whole story here — Leqembi is the flagship growth pillar management has spent years selling to the Street as the proof Biogen escaped its multiple sclerosis-franchise decline, and that pillar sits entirely on the durability of NCD 200.3's language on eligible diagnosis, amyloid confirmation, and registry participation. Any narrowing of who "qualifies" doesn't just slow growth, it directly shrinks the prescribable population. Regeneron REGN carries adjacent, smaller exposure through its own neuro-antibody pipeline ambitions, which lean on the same coverage architecture and CED evidentiary precedent Leqembi established — a stricter bar for one amyloid drug is a stricter bar for the class.
The play / what to watch: Watch CMS's National Coverage Analysis tracker and any new Medicare Coverage Database posting under NCD 200.3 for a reopened comment period — that's the trigger, not an FDA action. Also watch HHS budget and advisory-committee signals for language singling out "high-cost, low-benefit" chronic therapies. A reopened NCD proceeding is the single most under-priced catalyst in large-cap biotech right now.
Source: original report ↗
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $40/moJoin the owners who run ahead of the industry. Cancel anytime, one click.